In focus · trending topic

EPIDERMOLYSIS BULLOSA

12 stories · following the connections

ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

By Nasdaq OMXApr 30, 2018, 11:00 AM UTC

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

By Nasdaq OMXNov 29, 2017, 12:00 PM UTC

ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

By Nasdaq OMXSep 19, 2017, 11:01 AM UTC

ProQR Announces Results for the Second Quarter of 2017

By Nasdaq OMXAug 16, 2017, 11:00 AM UTC

ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

By Nasdaq OMXMar 27, 2017, 11:02 AM UTC

ProQR to Present at Two Upcoming Investor Conferences in March

By Nasdaq OMXMar 1, 2017, 12:01 PM UTC

ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

By Nasdaq OMXFeb 28, 2017, 12:01 PM UTC

ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

By Nasdaq OMXFeb 28, 2017, 12:01 PM UTC